First Trust Advisors LP Has $19.02 Million Position in Henry Schein, Inc. (NASDAQ:HSIC)

Posted by Defense World Staff on Mar 10th, 2023

First Trust Advisors LP lessened its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC – Get Rating) by 11.7% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 289,167 shares of the company’s stock after selling 38,322 shares during the period. First Trust Advisors LP owned 0.21% of Henry Schein worth $19,018,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its stake in Henry Schein by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 15,331,533 shares of the company’s stock worth $1,336,756,000 after acquiring an additional 214,846 shares during the period. Pendal Group Ltd increased its stake in Henry Schein by 26.0% during the 3rd quarter. Pendal Group Ltd now owns 4,414,378 shares of the company’s stock worth $290,334,000 after acquiring an additional 910,179 shares during the period. Macquarie Group Ltd. increased its stake in Henry Schein by 7.9% during the 3rd quarter. Macquarie Group Ltd. now owns 2,434,865 shares of the company’s stock worth $159,915,000 after acquiring an additional 178,783 shares during the period. FMR LLC increased its stake in Henry Schein by 189.6% during the 2nd quarter. FMR LLC now owns 2,179,126 shares of the company’s stock worth $167,226,000 after acquiring an additional 1,426,767 shares during the period. Finally, Massachusetts Financial Services Co. MA bought a new position in Henry Schein during the 2nd quarter worth $159,204,000. Institutional investors own 95.45% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on HSIC shares. Credit Suisse Group decreased their price target on Henry Schein from $99.00 to $97.00 and set an “outperform” rating on the stock in a research note on Tuesday, February 28th. Morgan Stanley decreased their price target on Henry Schein from $70.00 to $69.00 and set an “underweight” rating on the stock in a research note on Tuesday, February 21st. Barrington Research decreased their price target on Henry Schein from $99.00 to $92.00 and set an “outperform” rating on the stock in a research note on Friday, February 17th. Piper Sandler lifted their price target on Henry Schein from $85.00 to $97.00 and gave the company an “overweight” rating in a research note on Monday, February 6th. Finally, UBS Group lifted their price target on Henry Schein from $75.00 to $82.00 and gave the company a “neutral” rating in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $85.89.

Insider Activity at Henry Schein

In related news, CEO Bradford C. Connett sold 6,840 shares of the firm’s stock in a transaction that occurred on Wednesday, December 21st. The shares were sold at an average price of $80.71, for a total transaction of $552,056.40. Following the completion of the sale, the chief executive officer now owns 55,412 shares of the company’s stock, valued at $4,472,302.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Henry Schein news, CEO Bradford C. Connett sold 6,840 shares of Henry Schein stock in a transaction that occurred on Wednesday, December 21st. The shares were sold at an average price of $80.71, for a total value of $552,056.40. Following the completion of the sale, the chief executive officer now owns 55,412 shares of the company’s stock, valued at approximately $4,472,302.52. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Philip A. Laskawy sold 6,405 shares of Henry Schein stock in a transaction on Friday, March 3rd. The shares were sold at an average price of $78.74, for a total value of $504,329.70. Following the transaction, the director now owns 26,239 shares in the company, valued at $2,066,058.86. The disclosure for this sale can be found here. Insiders sold 82,802 shares of company stock valued at $6,694,575 over the last 90 days. Corporate insiders own 1.00% of the company’s stock.

Henry Schein Trading Down 0.7 %

Henry Schein stock opened at $77.25 on Friday. The stock has a market cap of $10.14 billion, a P/E ratio of 19.86, a PEG ratio of 1.79 and a beta of 0.80. The company has a debt-to-equity ratio of 0.25, a quick ratio of 0.91 and a current ratio of 1.79. Henry Schein, Inc. has a fifty-two week low of $64.75 and a fifty-two week high of $92.68. The firm’s fifty day moving average price is $82.36 and its 200-day moving average price is $77.14.

Henry Schein (NASDAQ:HSIC – Get Rating) last posted its earnings results on Thursday, February 16th. The company reported $1.35 earnings per share for the quarter, topping analysts’ consensus estimates of $1.21 by $0.14. Henry Schein had a net margin of 4.25% and a return on equity of 15.79%. The company had revenue of $3.37 billion during the quarter, compared to analyst estimates of $3.37 billion. During the same period in the prior year, the business posted $1.07 earnings per share. Henry Schein’s revenue for the quarter was up 1.2% on a year-over-year basis. Equities research analysts forecast that Henry Schein, Inc. will post 5.34 earnings per share for the current fiscal year.

Henry Schein Company Profile

(Get Rating)

Henry Schein, Inc engages in the provision of health care products and services to medical, dental, and veterinary office-based practitioners. It operates through the Healthcare Distribution, and Technology and Value-Added Services segments. The Healthcare Distribution segment includes consumable products, laboratory, small and large equipment repair services, branded and generic pharmaceuticals, vaccines, surgicals, diagnostic tests, infection-control products and vitamins.